TokenPost·
Neurocrine Expects INGREZZA Revenue Growth in 2027 on Volume Gains
Chief Financial Officer Matthew Abernethy expects double-digit volume growth to outweigh pricing pressure. Formal 2027 sales guidance is due in February.
More news
- TokenPostTsakos Board Declares $0.578125 Dividend on Series E Preferred Shares
- TokenPostPetrus Resources Sets Nov. 27 Payment for $0.01 Monthly Dividend
- TokenPostPaycom Declares $0.375 Quarterly Cash Dividend for Dec. 7 Payment
- Bitcoin.com NewsThai Police Get Shuffle Crypto Casino Money-Trail Data From 3 Exchanges
- TokenPostMidland States Sets $0.4844 Dividend Per Series A Depositary Share
- TokenPostWatts Water Technologies Declares $0.63 Quarterly Dividend